Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

At 10.5% CAGR, Vaccine Adjuvants Market Revenue to Cross $ 1400.1 Million by 2027; Brandessence Market Research

This image opens in the lightbox

News provided by

Brandessence Market Research And Consulting Private Limited

11 May, 2021, 14:53 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, May 11, 2021 /PRNewswire/ -- Global demand for Vaccine Adjuvants Market Size, in terms of revenue, was worth of USD 696 Million in 2020 and is expected to reach USD 1400.1 Million in 2027, growing at a CAGR of 10.5% from 2020 to 2027. The global Vaccine Adjuvants is expected to grow at a significant rate due to the number of driving factors in Healthcare industry.

Factors such as increasing prevalence of infectious diseases, rising participation of pharma companies, growing geriatric population and increasing funding by government bodies are propelling growth of the market.

Get Sample Copy of this report@ https://brandessenceresearch.com/requestSample/PostId/1535

Vaccine Adjuvants is known as non-specific immune-potentiators that give signals and activate immune-recognition pathways. Adjuvants is able to sustain and robust immune responses to some bacteria and viruses for long duration. Adjuvants develops superior immune system in patients. Adjuvants is used to enhance the potency of vaccines. Incorporation of an Adjuvants into a vaccine can amplify, guide and/or accelerate the immune response towards the most effective form for each infection or malignancy. They are essential components of subunit as well as certain inactivated vaccines as they induce specific immune responses that are more robust and long-lasting. Sometimes Adjuvants containing vaccines can cause more local reactions like redness, swelling, and pain at the injection site. There are several adjutants are available such as aluminum, AS04, MF59, AS01B, CpG 1018. Most commonly used adjutants are aluminum salt-based adjutants and emulsion adjutants. Adjutants are used to enhance speed and duration of immune system.

Covid-19 has shown a positive on the growth of global vaccine Adjuvants market as cases of covid-19 are rising and there is more demand of Adjuvantsed vaccines all over the world. However, supply chains of vaccine distribution are disturbed due to lockdown in various countries which shows some decline impact as well but over all demand of vaccine.

Increasing Prevalence of Infectious Diseases, Rising Participation of Pharma Companies, Growing Geriatric Population and Increasing Funding by Government Bodies are driving the Market Growth.

Factors such as increasing frequency of infectious diseases, rise in participation of pharma companies, growing geriatric population and supportive funding by government bodies are propelling growth of the market. Infectious diseases such as Ebola virus, SARS, MERS (Middle East Respiratory Syndrome) and currently on going Covid-19 pandemic are spreading rapidly all over the world. As all these are infectious diseases they can pass from person to person by direct or indirect contact. For example; According to WHO, globally there are 153,954,491 confirmed cases of covid-19, including 3,221,052 deaths. In addition, key players' launching new products is also propelling the growth of the market. Due to increasing demand of vaccine Adjuvants and increasing number of product offerings by key players of this market are also fostering the market growth. For instance; on May 2020, GlaxoSmithKline announced that it will produced one billion doses of pandemic vaccine Adjuvants in 2021 to support multiple Covid-19 vaccine collaborations.

However, side effects of some vaccine Adjuvants may hamper the growth of the market. In spite of that, advancement in Adjuvants technologies for the development of more effective vaccines can offer opportunities for further growth of the global vaccine Adjuvants market.

Get Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/1535

Global vaccine Adjuvants market is segmented on the basis type, route of administration, diseases and regional & country level. On the basis of type, global vaccine Adjuvants market is classified into pathogen components, Adjuvants emulsions, particulate Adjuvants and combination Adjuvants. On the basis of route of administration, global vaccine Adjuvants market is classified into oral, subcutaneous, intranasal, and intramuscular. On the basis of disease, global vaccine Adjuvants market is classified into cancer, rare diseases, autoimmune disorder and infectious disease.

Key players for Global Vaccine Adjuvants Market Report:

Some major key players of global vaccine Adjuvants market are Brenntag Biosector CSL Limited, SEPPIC Agenus, Inc. Novavax, Inc. SPI Pharma, Inc. Invivogen Avanti Polar Lipids, Inc. MVP Laboratories, Inc. and OZ Biosciences and others.

News: Valneva, Dynavax Announced Supply Agreement for Inactivated, Adjuvantsed COVID-19 Vaccine

On September 16th, 2020; Valneva and Dynavax Technologies announced a commercial partnership for the supply of Dynavax's CpG 1018 Adjuvants for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001. Valneva separately announced an agreement with the UK government to provide up to 190 million doses of VLA20011 over a five year period. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the option to purchase up to an additional 90 million doses through 2025. Valneva expects VLA2001 to enter clinical studies by the end of 2020 and to potentially reach regulatory approval in the second half of 2021. This commercial supply partnership follows Valneva and Dynavax's initial collaboration to advance COVID-19 vaccine development, announced in April 2020.

North America is Expected to Dominate the Global Vaccine Adjuvants Market

The global vaccine Adjuvants market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the market within the forecast period attributed to ongoing clinical trials for vaccine development, highly developed healthcare infrastructure and high investment in research & development activities in this region. For example; According to NCT (National Clinical Trials) on September 2020, there are 500 clinical trials are under development in united states, which showing increase in demand of vaccine Adjuvants market therefore ongoing clinical trials for vaccine development is propelling the growth of the market. In addition, increasing infectious diseases is also accelerating the growth of vaccine Adjuvants market in this region. Moreover, growth in findings by government bodies, increasing prevalence of cancer disease and ongoing research activating of vaccine development also is boosting the growth of the market.

Asia Pacific is also expected to witness a high growth rate in vaccine Adjuvants market due to increasing cases of covid-19 in this region. For example; according to Union health ministry, India recorded 1, 31,968 new Covid-19 cases and number of infections reached to 13,06,0542 which indicates increasing demand of vaccine Adjuvants market.

Complete Purchase of this Premium report: https://brandessenceresearch.com/Checkout?report_id=1535

Key Benefits of Global Vaccine Adjuvants Market Report:

  • Global Vaccine Adjuvants Market report covers in-depth historical and forecast analysis.
  • Global Vaccine Adjuvants Market research report provides detail information about Market Introduction, Market Summary, Global market, Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Global Vaccine Adjuvants Market report helps to identify opportunities in Marketplace.
  • Global Vaccine Adjuvants Market report covers extensive analysis of emerging Trends.

Vaccine Adjuvants Market By Regional & Country Level:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

Latin America

  • Brazil
  • Mexico

Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Complete Report of Vaccine Adjuvants Market: https://brandessenceresearch.com/healthcare/vaccine-adjuvant-market

Related Report

Homecare Oxygen Concentrators Market: Global Size, Trends, Competitive, Historical & Forecast Analysis 2021-2027

Pharmaceutical Robots Market Size to hit USD 251.76 Million by 2027

Prefilled Syringe market size is expected to reach USD 2633.4 Million in 2027

Vaccine Raw Material Market Size By Applications (Covid-19, Smallpox, Influenza, Measles, Mumps, Rubella, Polio, TB, Others), By End-User (Research Institute, Vaccine Manufacturers, Others) Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 – 2027

Dengue Testing Market is valued at USD 480.9 Million in 2018 and expected to reach USD 742.4 Million by 2025 with the CAGR of 6.4% over the forecast period. Introduction of cost-effective and reliable test kits and devices are anticipated to drive the growth of Global Dengue Testing Market.

About Brandessence Market Research & Consulting Pvt ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Website: https://brandessenceresearch.com Article: https://businessstatsnews.com

Media Contact:

Mr. Aniket Patil
Email: aniket@brandessenceresearch.com   
Email: vishal@brandessenceresearch.com  
Corporate Sales: +44-2038074155
Asia Office: +91-7447409162

Logo: https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg  

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.